BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; European Society for Medical Oncology (ESMO)., European Society of Surgical Oncology (ESSO)., European Society of Radiotherapy and Oncology (ESTRO). Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi57-63. [PMID: 24078663 DOI: 10.1093/annonc/mdt344] [Cited by in Crossref: 179] [Cited by in F6Publishing: 177] [Article Influence: 22.4] [Reference Citation Analysis]
Number Citing Articles
1 Mir TA, Malik AA, Wani MA, Rasool Z, Bari SU. Gastric Carcinoma—a New Biomarker Peritoneal Fluid Lavage Cytology. Indian J Surg. [DOI: 10.1007/s12262-022-03386-4] [Reference Citation Analysis]
2 Huang P, Liu Y, Jia B, Cao S. The Expression, Prognostic Value, and Immunological Correlation of MCEMP1 and its Potential Role in Gastric Cancer. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/8167496] [Reference Citation Analysis]
3 Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48. [PMID: 29445300 DOI: 10.2147/CMAR.S149619] [Cited by in Crossref: 339] [Cited by in F6Publishing: 218] [Article Influence: 84.8] [Reference Citation Analysis]
4 Ishido K, Higuchi K, Tanabe S, Azuma M, Sasaki T, Katada C, Komori S, Hayakawa K, Hosoda K, Yamashita K, Katada N, Koizumi W. Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy. Jpn J Radiol 2016;34:35-42. [PMID: 26576774 DOI: 10.1007/s11604-015-0502-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Hu HM, Tsai HJ, Ku HY, Lo SS, Shan YS, Chang HC, Chao Y, Chen JS, Chen SC, Chiang CJ, Li AF, Wang HP, Wang TE, Bai LY, Wu MS, Chen LT, Liu TW, Yang YH. Survival outcomes of management in metastatic gastric adenocarcinoma patients. Sci Rep 2021;11:23142. [PMID: 34848751 DOI: 10.1038/s41598-021-02391-z] [Reference Citation Analysis]
6 Wang Y, Guo S, Zhang J, Meng XY, Zheng ZC, Zhao Y. A SEER population analysis of stage IB resected gastric cancer: who can benefit from adjuvant therapy? Scand J Gastroenterol 2020;55:193-201. [PMID: 31976783 DOI: 10.1080/00365521.2020.1716062] [Reference Citation Analysis]
7 De Raffele E, Mirarchi M, Cuicchi D, Lecce F, Cola B. Evolving role of FDG-PET/CT in prognostic evaluation of resectable gastric cancer. World J Gastroenterol 2017; 23(38): 6923-6926 [PMID: 29097864 DOI: 10.3748/wjg.v23.i38.6923] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Yan ZJ, Wang JX, Liu YY, Li ZH, Zhang LJ, Gan P, Han X, Luan LK, Dai YG. A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy. Case Rep Gastrointest Med 2018;2018:3954260. [PMID: 30425863 DOI: 10.1155/2018/3954260] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Ossola P, Mascioli F, Coletta D, Bononi M. Laparoscopic Mesogastrium Excision for Gastric Cancer: Only the Beginning. J Laparoendosc Adv Surg Tech A 2021;31:371-4. [PMID: 33052765 DOI: 10.1089/lap.2020.0743] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Mingol F, Gallego J, Orduña A, Martinez-Blasco A, Sola-Vera J, Moya P, Morcillo MA, Ruiz JA, Calpena R, Lacueva FJ. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surg 2015;15:66. [PMID: 25997454 DOI: 10.1186/s12893-015-0054-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
11 Huang ZN, Desiderio J, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer-an east and west multicenter study. BMC Gastroenterol 2019;19:205. [PMID: 31791240 DOI: 10.1186/s12876-019-1096-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Liu K, Chen XZ, Zhang WH, Zhang DY, Luo Y, Yu Y, Yang K, Yang SJ, Chen XL, Sun LF, Zhao LY, Zhou ZG, Hu JK. "Four-Step Procedure" of laparoscopic exploration for gastric cancer in West China Hospital: a retrospective observational analysis from a high-volume institution in China. Surg Endosc 2019;33:1674-82. [PMID: 30478700 DOI: 10.1007/s00464-018-6605-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 Liu T, Chen L. S-1 with leucovorin for gastric cancer: how far can it go? The Lancet Oncology 2016;17:12-4. [DOI: 10.1016/s1470-2045(15)00478-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Kaltsidis H, Mansoor W, Park JH, Song HY, Edwards DW, Laasch HU. Oesophageal stenting: Status quo and future challenges. Br J Radiol 2018;91:20170935. [PMID: 29888981 DOI: 10.1259/bjr.20170935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lee KG, Shin CI, Kim SG, Choi J, Oh SY, Son YG, Suh YS, Kong SH, Lee HJ, Kim SH, Lee KU, Kim WH, Yang HK. Can endoscopic ultrasonography (EUS) improve the accuracy of clinical T staging by computed tomography (CT) for gastric cancer? Eur J Surg Oncol 2021;47:1969-75. [PMID: 33741246 DOI: 10.1016/j.ejso.2021.02.031] [Reference Citation Analysis]
16 Morgagni P, Tringali D, La Barba G, Vittimberga G, Ercolani G. Historical assumptions of lymphadenectomy. Transl Gastroenterol Hepatol 2016;1:90. [PMID: 28138655 DOI: 10.21037/tgh.2016.11.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Sollini M, Calabrese L, Zangheri B, Erba PA, Gramaglia A, Gasparini M. (18)F-FDG PET/CT versus bone scintigraphy in the follow-up of gastric cancer. Rev Esp Med Nucl Imagen Mol. 2016;35:121-123. [PMID: 26653282 DOI: 10.1016/j.remn.2015.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Tsuji T, Isobe T, Seto Y, Tanaka C, Kojima K, Motoori M, Ikeda M, Nitta T, Oshio A, Nakada K. Effects of creating a jejunal pouch on postoperative quality of life after total gastrectomy: A cross‐sectional study. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12497] [Reference Citation Analysis]
19 Lu J, Zheng ZF, Wang W, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Zhou ZW, Huang CM, Zheng CH, Li P. A novel TNM staging system for gastric cancer based on the metro-ticket paradigm: a comparative study with the AJCC-TNM staging system. Gastric Cancer 2019;22:759-68. [PMID: 30612230 DOI: 10.1007/s10120-018-00904-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
20 Wang M, Busuttil RA, Pattison S, Neeson PJ, Boussioutas A. Immunological battlefield in gastric cancer and role of immunotherapies. World J Gastroenterol 2016; 22(28): 6373-6384 [PMID: 27605873 DOI: 10.3748/wjg.v22.i28.6373] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
21 Lin TY, Lan WH, Chiu YF, Feng CL, Chiu CH, Kuo CJ, Lai CH. Statins' Regulation of the Virulence Factors of Helicobacter pylori and the Production of ROS May Inhibit the Development of Gastric Cancer. Antioxidants (Basel) 2021;10:1293. [PMID: 34439541 DOI: 10.3390/antiox10081293] [Reference Citation Analysis]
22 Zou L, Qian J. Decline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinoma. Chin J Cancer Res. 2014;26:404-409. [PMID: 25232212 DOI: 10.3978/j.issn.1000-9604.2014.07.02] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
23 Angelov KG, Vasileva MB, Grozdev KS, Toshev SY, Sokolov MB, Todorov GT. The impact of the extent of surgical resection on survival of gastric cancer patients. Onco Targets Ther. 2016;9:4687-4694. [PMID: 27555787 DOI: 10.2147/ott.s97699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Russo A, Li P, Strong VE. Differences in the multimodal treatment of gastric cancer: East versus west. J Surg Oncol 2017;115:603-14. [PMID: 28181265 DOI: 10.1002/jso.24517] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
25 D’ugo D, Biondi A, Tufo A, Baiocchi G, Persiani R. Surveillance After Gastric Resection. In: Strong VE, editor. Gastric Cancer. Cham: Springer International Publishing; 2015. pp. 255-70. [DOI: 10.1007/978-3-319-15826-6_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Abdelfatah MM, Barakat M, Lee H, Kim JJ, Uedo N, Grimm I, Othman MO. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis. Gastrointest Endosc. 2018;87:338-347. [PMID: 28966062 DOI: 10.1016/j.gie.2017.09.025] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 9.8] [Reference Citation Analysis]
27 Wang Y, Zhang J, Guo S, Dong Z, Meng X, Zheng G, Yang D, Zheng Z, Zhao Y. Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis. Clin Transl Oncol 2019;21:1499-509. [PMID: 30903518 DOI: 10.1007/s12094-019-02078-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
28 Berlth F, Kim WH, Choi JH, Park SH, Kong SH, Lee HJ, Yang HK. Prognostic Impact of Frozen Section Investigation and Extent of Proximal Safety Margin in Gastric Cancer Resection. Ann Surg 2020;272:871-8. [PMID: 32833759 DOI: 10.1097/SLA.0000000000004266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
29 Aguiar PN Jr, Tadokoro H, Forones NM, de Mello RA. Treating operable patients with gastric cancer: Macdonald's protocol versus adjuvant chemotherapy. Future Oncol 2015;11:2247-9. [PMID: 26260801 DOI: 10.2217/fon.15.141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
30 Chapelle N, Bouvier AM, Manfredi S, Drouillard A, Lepage C, Faivre J, Jooste V. Early Gastric Cancer: Trends in Incidence, Management, and Survival in a Well-Defined French Population. Ann Surg Oncol 2016;23:3677-83. [PMID: 27216743 DOI: 10.1245/s10434-016-5279-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
31 Nilsson M. Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer 2017;20:135-40. [PMID: 27718134 DOI: 10.1007/s10120-016-0654-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
32 Miao RL, Wu AW. Towards personalized perioperative treatment for advanced gastric cancer. World J Gastroenterol 2014; 20(33): 11586-11594 [PMID: 25206266 DOI: 10.3748/wjg.v20.i33.11586] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
33 Okabe H, Hata H, Ueda S, Zaima M, Tokuka A, Yoshimura T, Ota S, Kinjo Y, Yoshimura K, Sakai Y; Kyoto University Surgical Oncology Group (KUSOG). A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03. J Surg Oncol 2016;113:36-41. [PMID: 26604064 DOI: 10.1002/jso.24096] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
34 Zanotti D, Baiocchi GL, Coniglio A, Mohammadi B, Ministrini S, Mughal M, Tiberio GAM, Dawas K. Follow-up after surgery for gastric cancer: how to do it. Updates Surg 2018;70:293-9. [DOI: 10.1007/s13304-018-0524-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Wu M, Wang Y, Liu H, Song J, Ding J. Genomic analysis and clinical implications of immune cell infiltration in gastric cancer. Biosci Rep 2020;40:BSR20193308. [PMID: 32338286 DOI: 10.1042/BSR20193308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 de Manzoni G, Verlato G, Bencivenga M, Marrelli D, Di Leo A, Giacopuzzi S, Cipollari C, Roviello F. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. Eur J Surg Oncol. 2015;41:534-540. [PMID: 25707350 DOI: 10.1016/j.ejso.2015.01.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
37 Moorcraft SY, Fontana E, Cunningham D, Peckitt C, Waddell T, Smyth EC, Allum W, Thompson J, Rao S, Watkins D, Starling N, Chau I. Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer 2016;16:112. [PMID: 26883815 DOI: 10.1186/s12885-016-2145-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
38 Fernandez E, Cacheux W, Frossard J, Koessler T, Abou M, Moniez M, Huber O, Puppa G, Roth A. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma. Digestive and Liver Disease 2017;49:552-6. [DOI: 10.1016/j.dld.2016.12.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Yang H, Berlth F. Gastric cancer surgery: the importance of technique and not only the extent of lymph node dissection. The Lancet Oncology 2019;20:329-31. [DOI: 10.1016/s1470-2045(19)30073-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Mogal H, Fields R, Maithel SK, Votanopoulos K. In Patients with Localized and Resectable Gastric Cancer, What is the Optimal Extent of Lymph Node Dissection-D1 Versus D2 Versus D3? Ann Surg Oncol. 2019;26:2912-2932. [PMID: 31076930 DOI: 10.1245/s10434-019-07417-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
41 Che K, Liu F, Wu N, Liu Q, Yuan L, Wei J. Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer. Cancer Med 2020;9:7137-50. [PMID: 32810384 DOI: 10.1002/cam4.3350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Negoi I, Runcanu A, Paun S, Negoi RI, Beuran M. Resection of Large Metachronous Liver Metastasis with Gastric Origin: Case Report and Review of the Literature. Cureus 2016;8:e814. [PMID: 27843732 DOI: 10.7759/cureus.814] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
43 Lin R, Fan N, Wu G, Chen Y, Guo Z, Wang X, Jin F, Chen L, Liu J. A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer. Journal of Chemotherapy 2014;27:52-6. [DOI: 10.1179/1973947814y.0000000198] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Wang ZX, Li GX, Zhou ZW, Huang ZP, Wang F, Xu RH. Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. Br J Surg 2017;104:1226-34. [PMID: 28449182 DOI: 10.1002/bjs.10550] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
45 Wang M, Huang YK, Kong JC, Sun Y, Tantalo DG, Yeang HXA, Ying L, Yan F, Xu D, Halse H, Di Costanzo N, Gordon IR, Mitchell C, Mackay LK, Busuttil RA, Neeson PJ, Boussioutas A. High-dimensional analyses reveal a distinct role of T-cell subsets in the immune microenvironment of gastric cancer. Clin Transl Immunology 2020;9:e1127. [PMID: 32377339 DOI: 10.1002/cti2.1127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
46 Mengardo V, Bencivenga M, Weindelmayer J, Pavarana M, Giacopuzzi S, de Manzoni G. Para-aortic lymphadenectomy in surgery for gastric cancer: current indications and future perspectives. Updates Surg 2018;70:207-11. [PMID: 29846892 DOI: 10.1007/s13304-018-0549-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
47 Pericay C, Rivera F, Gomez-Martin C, Nuñez I, Cassinello A, Imedio ER. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Med 2016;5:3464-74. [PMID: 27774774 DOI: 10.1002/cam4.941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Stahl KA, Olecki EJ, Dixon ME, Peng JS, Torres MB, Gusani NJ, Shen C. Gastric Cancer Treatments and Survival Trends in the United States. Curr Oncol 2020;28:138-51. [PMID: 33704182 DOI: 10.3390/curroncol28010017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Garbarino GM, Costa G, Laracca GG, Castagnola G, Mercantini P, Di Paola M, Vita S, Masoni L. Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer in middle-low-volume centers in Western countries: a propensity score matching analysis. Langenbecks Arch Surg 2020;405:797-807. [PMID: 32754848 DOI: 10.1007/s00423-020-01951-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Guo DJ, Yang K, Zhang WH, Chen XL, Chen XZ, Zhang B, Zhou ZG, Hu JK. Prognostic Value of Metastatic No.8p LNs in Patients with Gastric Cancer. Gastroenterol Res Pract 2015;2015:937682. [PMID: 26649037 DOI: 10.1155/2015/937682] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Chin YK, Iglesias-Garcia J, de la Iglesia D, Lariño-Noia J, Abdulkader-Nallib I, Lázare H, Rebolledo Olmedo S, Dominguez-Muñoz JE. Accuracy of endoscopic ultrasound-guided tissue acquisition in the evaluation of lymph nodes enlargement in the absence of on-site pathologist. World J Gastroenterol 2017; 23(31): 5755-5763 [PMID: 28883701 DOI: 10.3748/wjg.v23.i31.5755] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
52 Cravo M, Fidalgo C, Garrido R, Rodrigues T, Luz G, Palmela C, Santos M, Lopes F, Maio R. Towards curative therapy in gastric cancer: Faraway, so close!. World J Gastroenterol 2015; 21(41): 11609-11620 [PMID: 26556990 DOI: 10.3748/wjg.v21.i41.11609] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
53 Bencivenga M, Verlato G, Mengardo V, Weindelmayer J, Allum WH. Do all the European surgeons perform the same D2? The need of D2 audit in Europe. Updates Surg 2018;70:189-95. [PMID: 29869322 DOI: 10.1007/s13304-018-0542-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Bara Jr T, Gurzu S, Jung I, Kadar Z, Sugimura H, Bara T. Single skip metastasis in sentinel lymph node: In an early gastric cancer. World J Gastroenterol 2015; 21(33): 9803-9807 [PMID: 26361428 DOI: 10.3748/wjg.v21.i33.9803] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
55 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
56 Li Z, Wang Y, Shan F, Ying X, Wu Z, Xue K, Miao R, Zhang Y, Ji J. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer 2018;21:977-87. [PMID: 29748876 DOI: 10.1007/s10120-018-0830-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
57 Choi YY, Noh SH, Cheong JH. Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. J Pathol Transl Med. 2016;50:1-9. [PMID: 26498010 DOI: 10.4132/jptm.2015.09.10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
58 Li W, Liu J. Overexpression of the zinc-α2-glycoprotein accelerates apoptosis and inhibits growth via the mTOR/PTEN signaling pathway in gastric carcinoma cells. Life Sci 2020;240:117117. [PMID: 31790689 DOI: 10.1016/j.lfs.2019.117117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 D'Ugo D, Agnes A, Grieco M, Biondi A, Persiani R. Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. Updates Surg 2020;72:355-78. [PMID: 32306277 DOI: 10.1007/s13304-020-00771-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Terazawa T, Matsuyama J, Goto M, Kawabata R, Endo S, Imano M, Fujita S, Akamaru Y, Taniguchi H, Tatsumi M, Lee SW, Kurisu Y, Kawakami H, Kurokawa Y, Shimokawa T, Sakai D, Kato T, Fujitani K, Satoh T. A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist 2020;25:119-e208. [PMID: 32043772 DOI: 10.1634/theoncologist.2019-0601] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates Surg 2020;72:1-19. [PMID: 32112342 DOI: 10.1007/s13304-020-00723-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Lichthardt S, Kerscher A, Dietz UA, Jurowich C, Kunzmann V, von Rahden BH, Germer CT, Wiegering A. Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer. BMC Cancer 2016;16:650. [PMID: 27538392 DOI: 10.1186/s12885-016-2708-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
63 Zurleni T, Gjoni E, Altomare M, Rausei S. Conversion surgery for gastric cancer patients: A review. World J Gastrointest Oncol 2018; 10(11): 398-409 [PMID: 30487951 DOI: 10.4251/wjgo.v10.i11.398] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
64 Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. J Clin Oncol. 2016;34:2721-2727. [PMID: 27298411 DOI: 10.1200/jco.2015.65.7692] [Cited by in Crossref: 115] [Cited by in F6Publishing: 65] [Article Influence: 19.2] [Reference Citation Analysis]
65 O'Brien S, Twomey M, Moloney F, Kavanagh RG, Carey BW, Power D, Maher MM, O'Connor OJ, Ó'Súilleabháin C. Sarcopenia and Post-Operative Morbidity and Mortality in Patients with Gastric Cancer. J Gastric Cancer 2018;18:242-52. [PMID: 30276001 DOI: 10.5230/jgc.2018.18.e25] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
66 Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol 2016;146:647-69. [PMID: 28077399 DOI: 10.1093/ajcp/aqw206] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
67 Nostedt J, Gibson-Brokop L, Ghosh S, Seidler M, McCall M, Schiller D. Evaluating the utility of computed tomography of the chest for gastric cancer staging. Can J Surg 2020;63:E57-61. [PMID: 32031765 DOI: 10.1503/cjs.000319] [Reference Citation Analysis]
68 Boerner T, Graichen A, Jeiter T, Zemann F, Renner P, März L, Soeder Y, Schlitt HJ, Piso P, Dahlke MH. CRS-HIPEC Prolongs Survival but is Not Curative for Patients with Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol 2016;23:3972-7. [PMID: 27313067 DOI: 10.1245/s10434-016-5306-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
69 Da B, Jani N, Gupta N, Jayaram P, Kankotia R, Yao Yu C, Dinis-Ribeiro M, Buxbaum J. High-risk symptoms do not predict gastric cancer precursors. Helicobacter 2019;24:e12548. [PMID: 30412322 DOI: 10.1111/hel.12548] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
70 Stabile Ianora AA, Telegrafo M, Lucarelli NM, Lorusso V, Scardapane A, Niccoli Asabella A, Moschetta M. Comparison between CT Net enhancement and PET/CT SUV for N staging of gastric cancer: A case series. Ann Med Surg (Lond) 2017;21:1-6. [PMID: 28751975 DOI: 10.1016/j.amsu.2017.07.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
71 Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, Fukushima N, Fujitani K; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017;265:277-283. [PMID: 27280511 DOI: 10.1097/sla.0000000000001814] [Cited by in Crossref: 133] [Cited by in F6Publishing: 79] [Article Influence: 26.6] [Reference Citation Analysis]
72 Li Z, Ji J. Application of laparoscopy in the diagnosis and treatment of gastric cancer. Ann Transl Med 2015;3:126. [PMID: 26207254 DOI: 10.3978/j.issn.2305-5839.2015.03.29] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
73 Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C, Moschetta M, Rubini G. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. Medicine (Baltimore). 2015;94:e864. [PMID: 25997066 DOI: 10.1097/MD.0000000000000864] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
74 Barreto SG, Windsor JA. Redefining early gastric cancer. Surg Endosc. 2015;Epub ahead of print. [PMID: 25829068 DOI: 10.1007/s00464-015-4184-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
75 Xu Y, Li Z, Pan G, Wu H, Li J, Lin W, Chen J, Cai Z. Anatomical Findings and Short-term Efficacy of Fascial Anatomy-guided Infrapyloric Lymphadenectomy in Laparoscopic Radical Gastrectomy for Gastric Cancer. Surg Laparosc Endosc Percutan Tech 2021;31:434-8. [PMID: 33710103 DOI: 10.1097/SLE.0000000000000886] [Reference Citation Analysis]
76 Xu S, Feng L, Chen Y, Sun Y, Lu Y, Huang S, Fu Y, Zheng R, Zhang Y, Zhang R. Consistency mapping of 16 lymph node stations in gastric cancer by CT-based vessel-guided delineation of 255 patients. Oncotarget 2017;8:41465-73. [PMID: 28611300 DOI: 10.18632/oncotarget.18407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
77 Hao Y, Yu P, Qian F, Zhao Y, Shi Y, Tang B, Zeng D, Zhang C. Comparison of laparoscopy-assisted and open radical gastrectomy for advanced gastric cancer: A retrospective study in a single minimally invasive surgery center. Medicine (Baltimore) 2016;95:e3936. [PMID: 27336885 DOI: 10.1097/MD.0000000000003936] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
78 Neto C, Brito M, Lopes V, Peixoto H, Abelha A, Machado J. Application of Data Mining for the Prediction of Mortality and Occurrence of Complications for Gastric Cancer Patients. Entropy 2019;21:1163. [DOI: 10.3390/e21121163] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
79 Zhang W, Wang Y, Zhu Z, Zheng Y, Song B. Propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195. International Journal of Biological Macromolecules 2018;120:975-84. [DOI: 10.1016/j.ijbiomac.2018.08.173] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
80 Brown J, Liepa AM, Bapat B, Madhwani S, Lorenzen S, García-Foncillas J, Candrilli SD, Kaye JA. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. Eur J Cancer Care (Engl) 2020;29:e13213. [PMID: 31883156 DOI: 10.1111/ecc.13213] [Reference Citation Analysis]
81 Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C, Cervantes A. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev. 2014;40:692-700. [PMID: 24656602 DOI: 10.1016/j.ctrv.2014.03.002] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 14.6] [Reference Citation Analysis]
82 Sendur MA, Ozdemir N, Özatlı T, Yazıcı O, Aksoy S, Ekinci AS, Yazılıtaş D, Günaydın Y, Oksuzoglu B, Benekli M, Zengin N. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Med Oncol 2014;31:153. [PMID: 25099765 DOI: 10.1007/s12032-014-0153-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Xiao SM, Xu R, Tang XL, Ding Z, Li JM, Zhou X. Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report. Oncol Lett 2018;16:2085-90. [PMID: 30008904 DOI: 10.3892/ol.2018.8942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
84 Mohammad NH, ter Veer E, Ngai L, Mali R, van Oijen MG, van Laarhoven HW. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. Cancer Metastasis Rev 2015;34:429-41. [PMID: 26267802 DOI: 10.1007/s10555-015-9576-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
85 Zeeneldin AA, Ramadan H, El Gammal MM, Saber MM, Elgamal D, Sherisher MA. Gastric carcinoma at Tanta Cancer Center: a comparative retrospective clinico-pathological study of the elderly versus the non-elderly. J Egypt Natl Canc Inst 2014;26:127-37. [PMID: 25150128 DOI: 10.1016/j.jnci.2014.04.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
86 Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, Solej M, Degiuli M. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol 2018; 24(2): 274-289 [PMID: 29375213 DOI: 10.3748/wjg.v24.i2.274] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
87 Chen XZ, Zhang WH, Yang K, Zhang B, Chen ZX, Chen JP, Zhou ZG, Hu JK. Quantitative comparisons of summary receiver operating characteristics (sROC) curves among conventional serological tumor biomarkers for predicting gastric cancer in Chinese population. Tumour Biol. 2014;35:9015-9022. [PMID: 24906604 DOI: 10.1007/s13277-014-1986-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
88 Wu ZF, Cao QH, Wu XY, Chen C, Xu Z, Li WS, Yao XQ, Liu FK. Regional Arterial Infusion Chemotherapy improves the Pathological Response rate for advanced gastric cancer with Short-term Neoadjuvant Chemotherapy. Sci Rep. 2015;5:17516. [PMID: 26620627 DOI: 10.1038/srep17516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
89 Biondi A, Lirosi MC, D’Ugo D, Fico V, Ricci R, Santullo F, Rizzuto A, Cananzi FC, Persiani R. Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World J Gastrointest Oncol 2015; 7(12): 389-400 [PMID: 26690252 DOI: 10.4251/wjgo.v7.i12.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
90 Shin HJ, Choi YO, Roh CK, Son SY, Hur H, Han SU. ASO Author Reflections: Prediction of Survival Outcomes Based on Preoperative Clinical Parameters in Gastric Cancer. Ann Surg Oncol 2021. [PMID: 33682019 DOI: 10.1245/s10434-021-09785-3] [Reference Citation Analysis]
91 Ye W, Li Y, Fan L, Zhao Q, Yuan H, Tan B, Zhang Z. Effect of annexin A7 suppression on the apoptosis of gastric cancer cells. Mol Cell Biochem 2017;429:33-43. [PMID: 28176245 DOI: 10.1007/s11010-016-2934-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
92 Wu CX, Zhu ZH. Diagnosis and evaluation of gastric cancer by positron emission tomography. World J Gastroenterol 2014; 20(16): 4574-4585 [PMID: 24782610 DOI: 10.3748/wjg.v20.i16.4574] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
93 Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med 2015;12:355-61. [PMID: 26779372 DOI: 10.7497/j.issn.2095-3941.2015.0054] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
94 Ueno T, Iida M, Yoshino S, Takeda S, Kubota H, Higashida M, Oka Y, Tsuruta A, Matsumoto H, Nagano H. East Versus West: Differences in Surgical Management in Asia Compared with Europe and North America. Surg Clin North Am. 2017;97:453-466. [PMID: 28325197 DOI: 10.1016/j.suc.2016.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
95 Shinohara H, Kurahashi Y, Ishida Y. Gastric equivalent of the 'Holy Plane' to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson's historic schema. Gastric Cancer 2021;24:273-82. [PMID: 33387120 DOI: 10.1007/s10120-020-01142-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Kumamoto T, Kurahashi Y, Haruta S, Niwa H, Nakanishi Y, Ozawa R, Okumura K, Ishida Y, Shinohara H. Laparoscopic modified lymphadenectomy in gastric cancer surgery using systematic mesogastric excision: a novel technique based on a concept. Langenbecks Arch Surg 2019;404:369-74. [PMID: 30904933 DOI: 10.1007/s00423-019-01770-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Zachos I, Zachou K, Dalekos GN, Tzortzis V. Management of Patients with Liver Cirrhosis and Invasive Bladder Cancer: A Case-series. J Transl Int Med. 2019;7:29-33. [PMID: 30997354 DOI: 10.2478/jtim-2019-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
98 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014; 6(6): 145-155 [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
99 Tin AW, Smith E, Hepworth R, Walker J, Wilson D, Wadd N. Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma. J Geriatr Oncol 2018;9:569-74. [PMID: 29884598 DOI: 10.1016/j.jgo.2018.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Lisiecki R, Kruszwicka M, Spychała A, Murawa D. Prognostic significance, diagnosis and treatment in patients with gastric cancer and positive peritoneal washings. A review of the literature. Rep Pract Oncol Radiother 2017;22:434-40. [PMID: 28883764 DOI: 10.1016/j.rpor.2017.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
101 Pecqueux M, Fritzmann J, Adamu M, Thorlund K, Kahlert C, Reißfelder C, Weitz J, Rahbari NN. Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis. Oncotarget 2015;6:35564-78. [PMID: 26384352 DOI: 10.18632/oncotarget.5595] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
102 Abbassi-ghadi N, Durakovic S, Piessen G, Gatenby P, Sultan J, Preston SR. Laparoscopic versus open subtotal gastrectomy for adenocarcinoma of the stomach in a Western population: peri-operative and 5-year oncological outcomes. Surg Endosc 2020;34:3818-26. [DOI: 10.1007/s00464-019-07146-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
103 Chen ZM, Huang L, Li MM, Meng L, Ying SC, Xu AM. Inhibitory effects of isocryptotanshinone on gastric cancer. Sci Rep. 2018;8:9307. [PMID: 29915371 DOI: 10.1038/s41598-018-27638-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
104 Yan Y, Yang A, Lu L, Zhao Z, Li C, Li W, Chao J, Liu T, Fong Y, Fu W, Woo Y. Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study. Ann Surg Oncol. 2021;28:1428-1436. [PMID: 32862371 DOI: 10.1245/s10434-020-09070-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
105 Donswijk ML, Hess S, Mulders T, Lam MG. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies. PET Clin 2014;9:421-41, v-vi. [PMID: 26050945 DOI: 10.1016/j.cpet.2014.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
106 Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weißinger F, Schnoy E, Becker K. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer. 2015;51:569-576. [PMID: 25694417 DOI: 10.1016/j.ejca.2015.01.059] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
107 Norero E, Bustos M, Herrera ME, Cerda J, González P, Ceroni M, Martínez C, Briceño E, Rojas H, Cártes R, Lopez V, Hidalgo V, Báez S, Caracci M, Viñuela E, Díaz A. Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center. Eur J Surg Oncol 2016;42:94-102. [PMID: 26577767 DOI: 10.1016/j.ejso.2015.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
108 Guan E, Tian F, Liu Z. A novel risk score model for stomach adenocarcinoma based on the expression levels of 10 genes. Oncol Lett 2020;19:1351-67. [PMID: 31966067 DOI: 10.3892/ol.2019.11190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Căinap C, Nagy V, Gherman A, Cetean S, Laszlo I, Constantin AM, Căinap S. Classic tumor markers in gastric cancer. Current standards and limitations. Clujul Med 2015;88:111-5. [PMID: 26528057 DOI: 10.15386/cjmed-409] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
110 Kawakami H, Okamoto I. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer. 2016;19:687-695. [PMID: 26690587 DOI: 10.1007/s10120-015-0585-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
111 Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W, Fan Q, Xu J, Xu N, Bai Y, Pan Y, Xu Q, Bai W, Xia L, Gao Y, Wang W, Shu Y, Shen L. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018;21:782-791. [PMID: 29488121 DOI: 10.1007/s10120-018-0809-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
112 Van Laethem J, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson D, Allum W, Haustermans K, Lepage C, Matysiak-budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T. The multidisciplinary management of gastro-oesophageal junction tumours. Digestive and Liver Disease 2016;48:1283-9. [DOI: 10.1016/j.dld.2016.08.112] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
113 Verlato G, Giacopuzzi S, Bencivenga M, Morgagni P, Manzoni GD. Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer. World J Gastroenterol 2014; 20(36): 12883-12891 [PMID: 25278685 DOI: 10.3748/wjg.v20.i36.12883] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
114 Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V, Germer CT, Pelz J, Kerscher AG. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer 2015;15:73. [PMID: 25879885 DOI: 10.1186/s12885-015-1081-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
115 Creutzfeldt A, Suling A, Oechsle K, Mehnert A, Atanackovic D, Kripp M, Arnold D, Stein A, Quidde J. Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. BMC Palliat Care 2016;15:25. [PMID: 26928745 DOI: 10.1186/s12904-016-0101-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
116 Brieau B, Auzolle C, Pozet A, Tougeron D, Bouché O, Soibinet P, Coriat R, Prieux C, Lecomte T, Goujon G. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Dig Liver Dis. 2016;48:441-445. [PMID: 26775096 DOI: 10.1016/j.dld.2015.12.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
117 Park SJ, Park YS, Jung IS, Yoon H, Shin CM, Ahn SH, Park DJ, Kim HH, Kim N, Lee DH. Is endoscopic surveillance necessary for patients who undergo total gastrectomy for gastric cancer? PLoS One 2018;13:e0196170. [PMID: 29856747 DOI: 10.1371/journal.pone.0196170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
118 Choi YY, Cho M, Kwon IG, Son T, Kim HI, Choi SH, Cheong JH, Hyung WJ. Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. Yonsei Med J 2019;60:235-42. [PMID: 30799586 DOI: 10.3349/ymj.2019.60.3.235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
119 Li Z, Li Z, Zhang L, Liu Q, Wang Z, Zhang Z, Xiao G, Fu W, Wang X, Ye Y, Yu J, Li F, Chen L, Wang S, Ji J. Staging laparoscopy for locally advanced gastric cancer in Chinese patients: a multicenter prospective registry study. BMC Cancer 2018;18:63. [PMID: 29321007 DOI: 10.1186/s12885-017-3791-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
120 Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476-484. [PMID: 25038874 DOI: 10.1007/s10120-014-0402-y] [Cited by in Crossref: 199] [Cited by in F6Publishing: 189] [Article Influence: 24.9] [Reference Citation Analysis]
121 Claus J, Patel G, Ng T, Parker PJ. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy. Biochem Soc Trans 2014;42:831-6. [PMID: 25109965 DOI: 10.1042/BST20140043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
122 Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19:1-48. [PMID: 30944757 DOI: 10.5230/jgc.2019.19.e8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 34.3] [Reference Citation Analysis]
123 Duarte HO, Balmaña M, Mereiter S, Osório H, Gomes J, Reis CA. Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor. Int J Mol Sci 2017;18:E2262. [PMID: 29143776 DOI: 10.3390/ijms18112262] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
124 Perlaza P, Ortín J, Pagès M, Buxó E, Fernández-Esparrach G, Colletti PM, Rubello D, Mayoral M, Sánchez N, Ruiz C, Ginés A, Fuster D. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma? Clin Nucl Med 2018;43:402-10. [PMID: 29485442 DOI: 10.1097/RLU.0000000000002028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
125 Lee K, Lee JH, Kim JW, Kim J, Ahn S, Kim JH. Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer. J Cancer Res Clin Oncol 2016;142:687-97. [DOI: 10.1007/s00432-015-2075-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
126 Goetze OT, Al-Batran SE, Chevallay M, Mönig SP. Multimodal treatment in locally advanced gastric cancer. Updates Surg 2018;70:173-9. [PMID: 29946806 DOI: 10.1007/s13304-018-0539-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
127 Liu L, Bai Z, Ma X, Wang T, Yang Y, Zhang Z. Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin. Exp Ther Med 2016;11:846-52. [PMID: 26998002 DOI: 10.3892/etm.2016.2994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
128 Kim SM, An JY, Lee J, Sohn TS, Kim S. Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis. Ann Surg Oncol 2018;25:1616-24. [DOI: 10.1245/s10434-018-6434-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
129 Shinohara H, Kurahashi Y, Haruta S, Ishida Y, Sasako M. Universalization of the operative strategy by systematic mesogastric excision for stomach cancer with that for total mesorectal excision and complete mesocolic excision colorectal counterparts. Ann Gastroenterol Surg 2018;2:28-36. [PMID: 29863126 DOI: 10.1002/ags3.12048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
130 Bracale U, Corcione F, Pignata G, Andreuccetti J, Dolce P, Boni L, Cassinotti E, Olmi S, Uccelli M, Gualtierotti M, Ferrari G, De Martini P, Bjelović M, Gunjić D, Cuccurullo D, Sciuto A, Pirozzi F, Peltrini R. Impact of neoadjuvant therapy followed by laparoscopic radical gastrectomy with D2 lymph node dissection in Western population: A multi-institutional propensity score-matched study. J Surg Oncol 2021;124:1338-46. [PMID: 34432291 DOI: 10.1002/jso.26657] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Choi YY, Noh SH, Cheong JH. Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J 2015;56:1177-85. [PMID: 26256958 DOI: 10.3349/ymj.2015.56.5.1177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
132 He T, Yu D, Wang Z, Guo C, Chang Y, Wang D. Chaperonin-containing tailless complex polypeptide 1 subunit 6A links with aggravating tumor features and disease-free survival in surgical gastric cancer patients: a long-term follow-up study. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101913] [Reference Citation Analysis]
133 Best LM, Mughal M, Gurusamy KS. Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2016;3:CD011389. [PMID: 27030300 DOI: 10.1002/14651858.cd011389.pub2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
134 Bujok K, Glaeser H, Schuh W, Rau TT, Schmidt I, Fromm MF, Mandery K. Interplay between the prostaglandin transporter OATP2A1 and prostaglandin E2-mediated cellular effects. Cell Signal 2015;27:663-72. [PMID: 25433165 DOI: 10.1016/j.cellsig.2014.11.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Ucal Y, Durer ZA, Atak H, Kadioglu E, Sahin B, Coskun A, Baykal AT, Ozpinar A. Clinical applications of MALDI imaging technologies in cancer and neurodegenerative diseases. Biochim Biophys Acta Proteins Proteom 2017;1865:795-816. [PMID: 28087424 DOI: 10.1016/j.bbapap.2017.01.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
136 Yan D, Du Y, Dai G, Huang L, Xu Q, Yu P. Management Of Synchronous Krukenberg Tumors From Gastric Cancer: a Single-center Experience. J Cancer 2018;9:4197-203. [PMID: 30519320 DOI: 10.7150/jca.25593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
137 Cananzi FC, Biondi A, Cozzaglio L, D’Ugo D, Persiani R, Quagliuolo V. Preoperative chemotherapy in gastric cancer: expanding the indications, limiting the overuse. Gastric Cancer. 2015;18:200-201. [PMID: 24682591 DOI: 10.1007/s10120-014-0359-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
138 Quintana M, Toriz JA, Novick D, Jones K, Botello BS, Silva JA. Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review. Pharmacoecon Open 2018;2:191-201. [PMID: 29623621 DOI: 10.1007/s41669-017-0043-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
139 Agnes A, Biondi A, Laurino A, Strippoli A, Ricci R, Pozzo C, Persiani R, D'Ugo D. A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer. J Surg Oncol 2020;122:293-305. [PMID: 32350878 DOI: 10.1002/jso.25959] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Pereira AL, Magalhães L, Moreira FC, Reis-das-Mercês L, Vidal AF, Ribeiro-Dos-Santos AM, Demachki S, Anaissi AKM, Burbano RMR, Albuquerque P, Dos Santos SEB, de Assumpção PP, Ribeiro-Dos-Santos ÂKC. Epigenetic Field Cancerization in Gastric Cancer: microRNAs as Promising Biomarkers. J Cancer 2019;10:1560-9. [PMID: 31031866 DOI: 10.7150/jca.27457] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
141 Degiuli M, De Manzoni G, Di Leo A, D’Ugo D, Galasso E, Marrelli D, Petrioli R, Polom K, Roviello F, Santullo F, Morino M. Gastric cancer: Current status of lymph node dissection. World J Gastroenterol 2016; 22(10): 2875-2893 [PMID: 26973384 DOI: 10.3748/wjg.v22.i10.2875] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
142 Faiz Z, Hayashi T, Yoshikawa T. Lymph node dissection for gastric cancer: Establishment of D2 and the current position of splenectomy in Europe and Japan. Eur J Surg Oncol 2021;47:2233-6. [PMID: 33910779 DOI: 10.1016/j.ejso.2021.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Biondi A, Agnes A, Del Coco F, Pozzo C, Strippoli A, D'Ugo D, Persiani R. Preoperative therapy and long-term survival in gastric cancer: One size does not fit all. Surg Oncol. 2018;27:575-583. [PMID: 30217321 DOI: 10.1016/j.suronc.2018.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
144 Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer 2015;18:833-42. [PMID: 25214034 DOI: 10.1007/s10120-014-0423-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
145 Sisic L, Strowitzki MJ, Blank S, Nienhueser H, Dorr S, Haag GM, Jäger D, Ott K, Büchler MW, Ulrich A, Schmidt T. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis. Gastric Cancer 2018;21:552-68. [DOI: 10.1007/s10120-017-0751-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
146 Catenacci DV, Tesfaye A, Tejani M, Cheung E, Eisenberg P, Scott AJ, Eng C, Hnatyszyn J, Marina N, Powers J, Wainberg Z. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol 2019;15:2073-82. [PMID: 31094225 DOI: 10.2217/fon-2019-0141] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
147 Aguiar PN Jr, Muniz TP, Miranda RR, Tadokoro H, Forones NM, Monteiro ID, Castelo-Branco P, Janjigian YY, De Mello RA. Current advances in targeted therapies for metastatic gastric cancer: improving patient care. Future Oncol 2016;12:839-54. [PMID: 26838766 DOI: 10.2217/fon.15.348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Chen X, Chen S, Wang X, Nie R, Chen D, Xiang J, Lin Y, Chen Y, Peng J. Analysis and external validation of a nomogram to predict peritoneal dissemination in gastric cancer. Chin J Cancer Res 2020;32:197-207. [PMID: 32410797 DOI: 10.21147/j.issn.1000-9604.2020.02.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 Lazăr DC, Avram MF, Romoșan I, Cornianu M, Tăban S, Goldiș A. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. World J Gastroenterol 2018; 24(32): 3583-3616 [PMID: 30166856 DOI: 10.3748/wjg.v24.i32.3583] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 12.5] [Reference Citation Analysis]
150 Ebinger SM, Warschkow R, Tarantino I, Schmied BM, Güller U, Schiesser M. Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer 2016;19:723-34. [PMID: 26391158 DOI: 10.1007/s10120-015-0541-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
151 Werner S, Chen H, Butt J, Michel A, Knebel P, Holleczek B, Zörnig I, Eichmüller SB, Jäger D, Pawlita M, Waterboer T, Brenner H. Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. Sci Rep 2016;6:25467. [PMID: 27140836 DOI: 10.1038/srep25467] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
152 Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014;5:2866-80. [PMID: 24930887 DOI: 10.18632/oncotarget.2003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
153 Strandby RB, Svendsen LB, Fallentin E, Egeland C, Achiam MP. The Multidisciplinary Team Conference's Decision on M-Staging in Patients with Gastric- and Gastroesophageal Cancer is not Accurate without Staging Laparoscopy. Scand J Surg 2016;105:104-8. [PMID: 26261200 DOI: 10.1177/1457496915598760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
154 Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:446-464. [PMID: 28129524 DOI: 10.1200/jco.2016.69.4836] [Cited by in Crossref: 134] [Cited by in F6Publishing: 70] [Article Influence: 22.3] [Reference Citation Analysis]
155 Rosati R, Parise P, Giannone Codiglione F. Technical pro & cons of the laparoscopic lymphadenectomy. Transl Gastroenterol Hepatol 2016;1:93. [PMID: 28138658 DOI: 10.21037/tgh.2016.12.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
156 Yarema R, de Manzoni G, Fetsych T, Ohorchak M, Pliatsko M, Bencivenga M. On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer. World J Gastrointest Oncol 2016; 8(6): 489-497 [PMID: 27326318 DOI: 10.4251/wjgo.v8.i6.489] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
157 Beeharry MK, Zhang TQ, Liu WT, Gang ZZ. Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J Surg Oncol 2020;18:51. [PMID: 32151257 DOI: 10.1186/s12957-020-01819-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
158 Wang Q, Mao X, Luo F, Wang J. LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway. J Cell Mol Med 2021;25:9112-27. [PMID: 34427967 DOI: 10.1111/jcmm.16656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Fernández-Moreno MC, Martí-Obiol R, López F, Ortega J. Modified Devine Exclusion for Unresectable Distal Gastric Cancer in Symptomatic Patients. Case Rep Gastroenterol 2017;11:9-16. [PMID: 28203132 DOI: 10.1159/000452759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
160 Le AT, Tzeng CW. Does finding early recurrence improve outcomes, and at what cost? J Surg Oncol 2016;114:329-35. [PMID: 27393742 DOI: 10.1002/jso.24370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
161 Lee K, Lee H, Oh S, Yang J, Ahn H, Suh Y, Kong S, Kim T, Oh D, Im S, Lee KU, Kim WH, Bang Y, Yang H. Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System? Ann Surg Oncol 2016;23:1234-43. [DOI: 10.1245/s10434-015-4980-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
162 Moehler M, Mahlberg R, Heinemann V, Obermannová R, Kubala E, Melichar B, Weinmann A, Scigalla P, Tesařová M, Janda P, Hédouin-biville F, Mansoor W. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. Gastric Cancer 2017;20:358-67. [DOI: 10.1007/s10120-016-0618-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
163 Ho VKY, Jansen EPM, Wijnhoven BPL, Neelis KJ, van Sandick JW, Verhoeven RHA, Lemmens VEP, van Laarhoven HWM. Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer. Ann Surg Oncol 2017;24:3647-57. [PMID: 28831737 DOI: 10.1245/s10434-017-6048-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
164 Ciesielski M, Kruszewski WJ, Walczak J, Szajewski M, Szefel J, Wydra J, Buczek T, Czerepko M. Analysis of postoperative morbidity and mortality following surgery for gastric cancer. Surgeon volume as the most significant prognostic factor. Prz Gastroenterol 2017;12:215-21. [PMID: 29123584 DOI: 10.5114/pg.2017.70475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
165 Personeni N, Baretti M, Bozzarelli S, Spaggiari P, Rubino L, Tronconi MC, Fumagalli Romario U, Rosati R, Giordano L, Roncalli M, Santoro A, Rimassa L. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer 2017;20:428-37. [PMID: 27530622 DOI: 10.1007/s10120-016-0625-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
166 Shah MA, Kang Y, Thuss-patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-yge M, de Haas SL. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer 2019;22:803-16. [DOI: 10.1007/s10120-018-00923-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
167 Chen T, Yan D, Zheng Z, Yang J, Dong XDE. Evolution in the surgical management of gastric cancer: is extended lymph node dissection back in vogue in the USA? World J Surg Oncol. 2017;15:135. [PMID: 28716043 DOI: 10.1186/s12957-017-1204-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
168 Meiklejohn JA, Mimery A, Martin JH, Bailie R, Garvey G, Walpole ET, Adams J, Williamson D, Valery PC. The role of the GP in follow-up cancer care: a systematic literature review. J Cancer Surviv. 2016;10:990-1011. [PMID: 27138994 DOI: 10.1007/s11764-016-0545-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
169 Abozeid M, Rosato A, Sommaggio R. Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. Biomed Res Int 2017;2017:5791262. [PMID: 28781967 DOI: 10.1155/2017/5791262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
170 Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, Terashima M. Impact of clinical tumor-node-metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer 2017;20:448-56. [PMID: 27586236 DOI: 10.1007/s10120-016-0637-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
171 Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654-2664. [PMID: 27156933 DOI: 10.1016/s0140-6736(16)30354-3] [Cited by in Crossref: 856] [Cited by in F6Publishing: 627] [Article Influence: 142.7] [Reference Citation Analysis]
172 Turanli S, Bozdogan N, Mersin H, Berberoglu U. The Effect of Helicobacter pylori on Gastric Cancer Treated with Adjuvant Chemotherapy After Curative Resection. Indian J Surg. 2015;77:489-494. [PMID: 26884656 DOI: 10.1007/s12262-015-1305-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
173 Yu P, Huang L, Cheng G, Yang L, Dai G, Ying J, Du Y. Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget 2017;8:82558-70. [PMID: 29137284 DOI: 10.18632/oncotarget.19759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
174 Tan E, Song J, Lam S, D'souza M, Crawford M, Sandroussi C. Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis. International Journal of Surgery 2019;72:59-68. [DOI: 10.1016/j.ijsu.2019.09.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
175 de Mestier L, Lardière-Deguelte S, Volet J, Kianmanesh R, Bouché O. Recent insights in the therapeutic management of patients with gastric cancer. Dig Liver Dis. 2016;48:984-994. [PMID: 27156069 DOI: 10.1016/j.dld.2016.04.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
176 Agnes A, Biondi A, Laurino A, Persiani R, D'Ugo D. Global updates in the treatment of gastric cancer: a systematic review. Part 1: staging, classification and surgical treatment. Updates Surg 2020;72:341-53. [PMID: 32157635 DOI: 10.1007/s13304-020-00736-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
177 Bencivenga M, Palla I, Scorsone L, Bortolami A, Mengardo V, Pavarana M, Turchetti G, de Manzoni G. Clinical pathways in gastric cancer care. Updates Surg 2018;70:279-91. [PMID: 29923079 DOI: 10.1007/s13304-018-0544-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
178 Wang LL, Zhang L, Cui XF. Downregulation of long noncoding RNA LINC01419 inhibits cell migration, invasion, and tumor growth and promotes autophagy via inactivation of the PI3K/Akt1/mTOR pathway in gastric cancer. Ther Adv Med Oncol. 2019;11:1758835919874651. [PMID: 31579114 DOI: 10.1177/1758835919874651] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
179 Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, Kono S, Kusano C, Itoi T, Fujimoto K, Moriyasu F, Grabsch HI. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer 2016;19:553-60. [PMID: 25987463 DOI: 10.1007/s10120-015-0502-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
180 Muneoka Y, Ohashi M, Kurihara N, Fujisaki J, Makuuchi R, Ida S, Kumagai K, Sano T, Nunobe S. Short- and long-term oncological outcomes of totally laparoscopic gastrectomy versus laparoscopy-assisted gastrectomy for clinical stage I gastric cancer. Gastric Cancer 2021;24:1140-9. [PMID: 33723719 DOI: 10.1007/s10120-021-01181-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Syn NL, Wee I, Shabbir A, Kim G, So JB. Pouch Versus No Pouch Following Total Gastrectomy: Meta-analysis of Randomized and Non-randomized Studies. Annals of Surgery 2019;269:1041-53. [DOI: 10.1097/sla.0000000000003082] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
182 Yang K, Choi YY, Zhang WH, Chen XZ, Song MK, Lee J, Zhang B, Chen ZX, Kim HI, Chen JP. Strategies to improve treatment outcome in gastric cancer: a retrospective analysis of patients from two high-volume hospitals in Korea and China. Oncotarget. 2016;7:44660-44675. [PMID: 27191995 DOI: 10.18632/oncotarget.9378] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
183 Cho JH, Lim JY, Cho JY. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS One 2017;12:e0186362. [PMID: 29040299 DOI: 10.1371/journal.pone.0186362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
184 Wei C, Liang T, Hsu C, Tsai C, Chen I. Laparoscopic versus open subtotal gastrectomy for locally advanced gastric cancer: A retrospective analysis from a single institution. Asian Journal of Surgery 2022. [DOI: 10.1016/j.asjsur.2022.03.046] [Reference Citation Analysis]
185 Gurzu S, Jung I, Kadar Z. Aberrant metastatic behavior and particular features of early gastric cancer. APMIS 2015;123:999-1006. [PMID: 26547366 DOI: 10.1111/apm.12469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
186 Miki Y, Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Perioperative risk assessment for gastrectomy by surgical apgar score. Ann Surg Oncol 2014;21:2601-7. [PMID: 24664626 DOI: 10.1245/s10434-014-3653-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
187 Yamamoto M, Rashid OM, Wong J. Surgical management of gastric cancer: the East vs. West perspective. J Gastrointest Oncol. 2015;6:79-88. [PMID: 25642341 DOI: 10.3978/j.issn.2078-6891.2014.097] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
188 Bohle W, Zachmann R, Zoller WG. Sequential endoscopic ultrasound identifies predictive variables for relapse-free follow-up after neoadjuvant chemotherapy in gastric cancer. Scand J Gastroenterol 2017;52:754-61. [PMID: 28355948 DOI: 10.1080/00365521.2017.1303845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]